-TheWire.in In a case that will once again prove that India is not out to arbitrarily purge all pharmaceutical patents, the Delhi high court has ruled in favour of Roche, a Swiss multinational. Many years ago, Roche dragged Cipla to court arguing that Cipla’s product infringed its patented anticancer drug, Erlotinib (brand name ‘Tarceva’). After a protracted legal battle fought over seven hard years, Roche finally won. But so did Cipla. Indeed,...

-DNA Despite a certain amount of progress in the past decade or so, the report points out glaring gaps in healthcare infrastructure in the country -- "low resource allocation, low emphasis on primary health care, poor utilisation of human resources," as Professor K Srinath Reddy, one of the co-authors said. Yet another report on India's troubled health care system pointed out the country's poor performance across health indicators, despite economic advantages....

-IANS Union Health Minister J.P. Nadda on Thursday said there was a need to set up a special task force comprising both government and private healthcare sectors to ensure quality healthcare for every citizen of India. "Our vision is to provide universal healthcare coverage despite several challenges in the health sector. It can better be done by a special task force comprising the ministry and representatives of private healthcare sector," Nadda said. He...

-The Times of India MUMBAI: When World AIDS Day is observed across the globe on December 1, India will enter the third, and perhaps the most perplexing decade of its HIVAIDS epidemic. The first 29 years were marked with victory as the human immunodeficiency virus (HIV) metamorphosed from being the deadliest word in public health to just another chronic disease such as diabetes or hypertension. that can be managed well with medicines....

-The Times of India NEW DELHI: In a move that comes as a huge relief to patients of chronic Hepatitis C, the apex committee of the Central drugs Standard Control Organisation (CDSCO) has granted a waiver of local trials for crucial new direct-acting antiviral drugs treating the disease. The waiver for sofosbuvir and ledipasvir co-formulation and for daclatasvir is expected to bring the generic version of these drugs, which cost a fraction...